You are here

Justice News

Department of Justice
U.S. Attorney’s Office
Eastern District of Virginia

FOR IMMEDIATE RELEASE
Friday, December 15, 2017

Man Sentenced for Conspiring to Distribute Opioids

ALEXANDRIA, Va. – An Alexandria man was sentenced today to 90 months in prison for his participation in a conspiracy to distribute oxycodone and methadone.

According to court documents, Robert T. Hancasky, III, 32, conspired with others, including his father, Robert T. Hancasky, Jr., to obtain oxycodone and methadone and distribute it to others. In particular, Hancasky, Jr. obtained oxycodone and methadone through a prescription from his doctor. The father and son duo then agreed to distribute these prescription opioids to customers and addicts in northern Virginia. Hancasky, III also participated in a scheme to obtain oxycodone by passing fraudulent prescriptions at local pharmacies. In furtherance of this scheme, Hancasky, III produced a fraudulent prescription for oxycodone, recruited “runners” to pass fake prescriptions at local pharmacies, and compensated the runners with oxycodone pills. In his plea papers, Hancasky, III also admitted to distributing heroin as well as buprenorphine, a Schedule III controlled substance.

 

Hancasky, Jr., pleaded guilty to his role in the conspiracy on December 8, and is scheduled to be sentenced on April 13, 2018.

 

Dana J. Boente, U.S. Attorney for the Eastern District of Virginia, and Andrew W. Vale, Assistant Director in Charge of the FBI’s Washington Field Office, made the announcement after sentencing by U.S. District Judge Liam O’Grady. Special Assistant U.S. Attorney Kyle Reynolds and Assistant U.S. Attorney Whitney Russell prosecuted the case.

A copy of this press release is located on the website of the U.S. Attorney’s Office for the Eastern District of Virginia. Related court documents and information is located on the website of the District Court for the Eastern District of Virginia or on PACER by searching for Case No. 1:17-cr-158.

Topic(s): 
Drug Trafficking
Prescription Drugs
Contact: 
Joshua Stueve Director of Communications joshua.stueve@usdoj.gov
Updated December 15, 2017